BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both the primary and secondary endpoints. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock performance was 10.94% in last session and finished the day at $9.99. Traded volume was 7.84million shares in the last session and the average volume of the stock remained 896.58K shares. The beta of the stock remained 2.69. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider ownership is 2.00%.

Dyax Corp. (NASDAQ:DYAX)‘s stock had its “buy” rating restated by investment analysts at BofA Merrill Lynch in a note issued to investors on Friday, 09 May 2014, Stock Ratings Network reports. Dyax Corp. (NASDAQ:DYAX) rose 27.42 percent to $8.41 Tuesday on volume of 6.39million shares. The intra-day range of the stock was $6.69 to $8.48. Dyax Corp. (NASDAQ:DYAX) has a market capitalization of $1.14billion.

Novavax, Inc. (NASDAQ:NVAX) gained 10.36% on 20 May 2014, recently the company declared follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine in 220 elderly adults (60 years of age and older, with a mean age of 68) that was initiated in October 2012. In the placebo-controlled trial, subjects received a single injection of either 60ug or 90ug of the RSV F-protein vaccine applicant, with or without aluminum phosphate as an adjuvant. On Tuesday, shares of Novavax, Inc. (NASDAQ:NVAX) advanced 5.77% to close the day at $5.13. Company return on investment (ROI) is -25.50% and its monthly performance is recorded as 31.88%. Novavax, Inc. (NASDAQ:NVAX) quarterly revenue growth is -15.62%.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), after the big top and breakaway gap a few weeks ago, it coiled very tightly and quietly, and suddenly picked up. It’s been up four days in a row, and on Tuesday, it took out the May 1st 7.65 line, up 48 cents, or 6.38%, on 2.6 million shares, closing at 8.00. It’s a beautiful chart. Looking for something around 11ish. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 6.38% in last session and finished the day at $8.00. Traded volume was 2.69million shares in the last session and the average volume of the stock remained 2.12million shares. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) insider ownership is 5.40%.